Evidence map›Paper›PMID 28662141›Full record

ArticlePloS one2017

SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.

Helena Pópulo, Rui Batista, Cristina Sampaio, Joana Pardal, José Manuel Lopes, Paula Soares

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Helena PópuloInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.ORCID http://orcid.org/0000-0002-6353-6879
Rui BatistaInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.
Cristina SampaioInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.
Joana PardalDepartment of Pathology, Hospital S. João, Porto, Portugal.
José Manuel LopesInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.
Paula SoaresInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.
Universidade do Porto · PTHospital de São João · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSDHD promoter mutations were reported in 4-10% of cutaneous melanomas. The advanced clinico-pathological and patient survival association with SDHD mutation and/or expression in cutaneous melanoma remains controversial.

objectivesTo evaluate the presence of SDHD promoter mutations and SDHD protein expression in a melanoma series and its possible association with prognosis and survival of the patients.

methodsWe assessed SDHD promoter status in cutaneous melanomas (CM), ocular melanomas (OM) and melanoma cell lines, and the expression of SDHD protein by immunohistochemistry in CM and OM, and by western blot in melanoma cell lines. We explored the putative association between SDHD protein expression and clinico-pathological and prognostic parameters of melanoma.

resultsWe detected 2% of SDHD promoter mutations in CM, but none in OM and cell lines. SDHD protein expression was present in all CM, in OM and in all CM and OM derived cell lines analysed. A significant association between lower SDHD mean protein expression and presence of ulceration and higher pT stage was found.

conclusionsSDHD promoter mutation seems to be a rare event in CM but SDHD lower expression might associate with worst prognostic features in CM.

Indexed as

MutationPromoter Regions, GeneticAdolescentAdultAgedAged, 80 and overCell Line, TumorChildCutaneous Malignant MelanomaFemaleHumansMaleMelanomaMiddle AgedPrognosisSkin NeoplasmsSDHD protein, humanSuccinate Dehydrogenase

Identifiers

PMID28662141
PMCPMC5491217
OpenAlexW2733742461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.